Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma

Table 2 List of patients with gene fusions

Risk group	ID	Sex	Age	Stage	Pathology	Chromosomal abnormality			Event	Fusion
High risk	N_SMC_001	M	3.8	Metastatic	GNB		11q		Recur/Dead	LUC7L3:KLC2
	N_SMC_006	M	3.1	Metastatic	PD		11q		Recur	CNTNAP4:RAB11FIP4
	N_SMC_011	M	3.3	Metastatic	GNB				CCDC32:CBX3* SAMD5:SASH1^$ HLA-C:HLA-A L1RAPL1:REPS2
	N_SMC_017	M	2.3	Metastatic	D		11q	17q		PPFIA1:GSDMA
	N_SMC_046	M	5.3	Metastatic	PD	1p				RALGPS2:DNAJC8
	N_SMC_049	M	6.1	Metastatic	PD		11q			RPN1:CCDC58
	N_SMC_070	F	4.6	Metastatic	UD			17q		FBXL7:CDKN3
	N_SMC_076	M	3.8	Metastatic	PD	1p	11q	17q		HP1BP3:NUP85
										MED8:ELOVL1
Non-high risk	N_SMC_003	M	10	Localized	GNB	1p				CCDC32:CBX3*
	N_SMC_026	F	4.1	Localized	GNB					CCDC32:CBX3*
	N_SMC_034	F	2.6	Localized	D			17q		CCDC32:CBX3* KCNH7:MAP3K19 PPP6R2:ANKIB1
	N_SMC_060	M	0.1	Localized	D		11q			MX1:FAM3B
	N_SMC_085	F	2.1	Localized	GNB			17q		CCDC32:CBX3*
	N_SMC_089	M	3.5	Localized	GNB					SAMD5:SASH1^$
	N_SMC_093	F	6.4	Localized	GNB					SAMD5:SASH1^$

UD undifferentiated, PD poorly differentiated, D differentiating, GNB ganglioneuroblastoma
There are two recurrent fusions *CCDC32:CBX3 ^$SAMD5:SASH1

ISSN: 1755-8794